Metaphor-Based Smoking Cessation Intervention
Condition(s) studied
Investigational drug(s) / intervention(s)
Metaphor-based smoking cessation intervention: Participants will receive a 100-day, WeChat-delivered smoking cessation intervention using metaphors such as "fog" and "restart" to describe smoking urges, nicotine dependence, and the process of behavior change. The intervention will provide staged messages on smoking-trigger identification, self-monitoring, action planning, coping strategies, environmental modification, social support, and relapse prevention, together with personalized feedback and a personalized journey map to help participants review their cessation experiences and progress.
5A's/5R's advice: The 5A's approach (Ask, Advise, Assess, Assist, and Arrange) will be used for participants who are ready to quit, and the 5R's approach (Relevance, Risks, Rewards, Roadblocks, and Repetition) will be used for participants who are not ready to quit.
Health warning leaflet: The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.
Study summary
This study aims to evaluate the effectiveness and participant experiences of a WeChat-delivered, metaphor-based smoking cessation intervention.
Eligibility
Primary outcome measure(s)
- Biochemical validated quit rate at 6 months follow-up — 6 months follow-up
The primary outcomes are biochemically validated quit rate (exhaled carbon monoxide \< 4 ppm or salivary cotinine \< 30 ng/ml)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Beijing Normal University | Zhuhai | Guangdong |
More Beijing Normal University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07803354 on ClinicalTrials.gov ↗ ← All trials in China